A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)
for Papulopustular Rosacea
Drug: Remibrutinib
1 location in El Paso
Sponsor: Novartis Pharmaceuticals
Sex: All·Age: 18+
Code: NCT07681271·Phase 2·Recruiting·Listed Jul 2, 2026